The emerging role of hypoxia-inducible factor-2 involved in chemo/radioresistance in solid tumors

Area of Science:

• Oncology
• Molecular Biology
• Cancer Research

Background:

• Solid tumors frequently exhibit hypoxia, a condition that impairs radio- and chemotherapy efficacy.
• Hypoxia-inducible factors (HIFs), including HIF-1, HIF-2, and HIF-3, are key regulators of cellular adaptation to low-oxygen environments.
• While HIF-1 is known to be associated with chemotherapy failure, emerging evidence highlights HIF-2's contribution to chemo- and radioresistance in solid tumors.

Purpose of the Study:

• To summarize the role of HIF-2 in chemo- and radioresistance within solid tumors.
• To elucidate the distinct mechanisms by which HIF-2 contributes to treatment resistance, differentiating it from HIF-1.
• To provide an overview of current research on HIF-2's pathological functions in hypoxic solid tumors.

Main Methods:

• Literature review and synthesis of existing research on HIF-2 function in cancer.
• Analysis of studies investigating the mechanisms of chemo- and radioresistance mediated by HIF-2.
• Comparative analysis of HIF-1α and HIF-2α roles in solid tumors under hypoxic conditions.

Main Results:

• HIF-2α exhibits divergent and sometimes opposing roles compared to HIF-1α in hypoxic solid tumors.
• HIF-2α contributes to chemo- and radioresistance through distinct mechanisms compared to HIF-1α.
• Accumulating evidence implicates HIF-2 in the development of treatment resistance in various solid tumors.

Conclusions:

• HIF-2 is a significant factor in the development of chemo- and radioresistance in solid tumors.
• Understanding HIF-2's unique mechanisms is crucial for developing novel therapeutic strategies against treatment-resistant cancers.
• Further research into HIF-2 pathways may reveal new targets for overcoming therapeutic challenges in hypoxic tumors.